Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lonafarnib + ritonavir + peginterferon alfa-2a
- Development stage
- Phase 2
- Lead developer
- Eiger BioPharmaceuticals
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
**lonafarnib + ritonavir + peginterferon alfa-2a** is a combination antiviral regimen explored for the treatment of viral hepatitis, particularly in chronic hepatitis D virus (HDV) infection. Lonafarnib is a synthetic farnesyltransferase inhibitor that disrupts viral assembly by inhibiting protein prenylation. Ritonavir is a small-molecule inhibitor of HIV protease, used here primarily as a pharmacokinetic booster to increase lonafarnib plasma levels by inhibiting CYP3A metabolism. Peginterferon alfa-2a is a recombinant, pegylated interferon which activates type I interferon receptors, upregulating the JAK/STAT pathway and driving innate antiviral responses. Studies demonstrate that this triple regimen achieves synergistic antiviral effects and enhanced reductions in HDV RNA compared to lonafarnib and ritonavir alone, with most robust responses observed when peginterferon alfa-2a is included[1].
- Other names
- LNFRTVPEG-IFNαPEG-IFNα-2a
02
Targets
FTase (Protein Farnesyltransferase)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on lonafarnib + ritonavir + peginterferon alfa-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lonafarnib + ritonavir + peginterferon alfa-2a.